Zongertinib shows promising results in HER2-mutant NSCLC, offering high response rates and improved quality of life with minimal toxicity.

Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to enhance the therapeutic efficacy of monoclonal antibodies, which is often limited by ...

Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab) covalently linked ...

AstraZeneca is currently recruiting participants for a Phase 3 clinical trial titled DESTINY-Biliary Tract Cancer-01, which aims to assess the efficacy and safety of Trastuzumab Deruxtecan (T-DXd ...

June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and patient well-being.

DATROWAY ® has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR- mutated non-small cell lung cancer who have received prior EGFR- directed ...

Julio César Chávez Jr creció en el infierno de las adicciones que atravesó su padre. Un recuento a su vida de excesos ...

DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive metastatic breast cancer.

Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511] ...

Etsy Cracks Down on 3D-Printed Designs, But Who Decides What's Original? The online marketplace now requires computerized creations from 3D printers, Cricuts, and CNC machines to be original ...